Valproic Acid Plasma Levels Down With Concomitant Meropenem

Share this content:
Valproic Acid Plasma Levels Down With Concomitant Meropenem
Valproic Acid Plasma Levels Down With Concomitant Meropenem

THURSDAY, Feb. 9, 2017 (HealthDay News) -- Concomitant use of valproic acid (VPA) and meropenem (MEPM) is associated with a decrease in VPA plasma levels, according to a study published online Feb. 1 in the Journal of Clinical Pharmacy and Therapeutics.

Z.-P. Wen, from Xiangya Hospital in Changsha, China, and colleagues conducted a retrospective analysis of 381 VPA therapeutic drug monitoring (TDM) records. VPA plasma levels were compared in different groups to examine the change in VPA level in the drug interaction with MEPM.

The researchers found that concomitant use of VPA and MEPM was associated with considerable decreases in VPA plasma level in both the 1.2 g/day (67.3 ± 4.6 versus 15.3 ± 1.9 µg/mL; P < 0.001) and 1.6 g/day (67.6 ± 1.2 versus 18.1 ± 2.6 µg/mL; P < 0.001) VPA groups. VPA plasma concentration did not differ significantly for the 1.2, 1.6, and 2.0 g/day VPA + MEPM groups (15.3 ± 1.9 µg/mL versus 18.1 ± 2.6 µg/mL versus 9.0 ± 3.0 µg/mL; P = 0.252). The MEPM daily dose did not affect the decrease in VPA concentration (14.0 ± 5.1 µg/mL versus 16.5 ± 1.9 µg/mL for high versus low MEPM daily dose; P = 0.729). VPA plasma concentration recovered to a value comparable to that before MEPM initiation after discontinuation of MEPM for more than seven days (69.7 ± 4.2 µg/mL versus 51.2 ± 8.1 µg/mL; P = 0.48).

"Our results imply that the decrease in drug concentration cannot be reversed by increasing VPA dose," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »